Smart science to improve lives™
Open search Basket 0 View basket

Speak with an expert

PHAD™ (MPLA Analogue)

Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells. PHAD is the first synthetic analogue of monophosphoryl lipid A (MPLA) derived from Salmonella minnesota. MPLA has been shown to be safe and effective in stimulating Th-1 type immune responses. Avanti developed PHAD as a synthetic alternative to the bacterial-derived MPLA, given its desirable vaccine design profile of low reactogenicity and high efficacy.

indicates required field
Please provide your first name
Please provide your last name
Please provide an email address
Please provide your company name
Please complete the recaptcha and resubmit the form.